A B S T R A C T To gain insight into the mechanism by which steroidal hormones influence the development of canine prostatic hyperplasia, nuclear and cytosolic androgen-and estrogen-receptor content, as measured under exchange conditions by the binding of[3H]R1881 (methyltrienolone) and [3H]estradiol, respectively, were quantitated in the prostates of purebred beagles ofknown age. In young dogs with spontaneously arising and experimentally induced (androstanediol plus estradiol treatment) prostatic hyperplasia, nuclear, but not cytosolic, prostatic androgen-receptor content was significantly greater than that determined in the normal prostates of age-matched dogs (3,452+222 and 4,035 ±274 fmol/mg DNA vs. 2,096±364 fmol/mg DNA, respectively). No differences were observed between the androgen-receptor content of the normal prostates of young dogs and the hyperplastic prostates of old dogs. The cytosolic and nuclear estrogen-receptor content of spontaneously arising prostatic hyperplasia in both young and old animals was similar to that found in normal prostates. The administration of estradiol plus androstanediol to castrate dogs significantly increased the prostatic nuclear androgen-receptor content over that found in dogs treated only with androstanediol. This estradiol-associated increase in nuclear androgenreceptor content was accompanied by the development of benign prostatic hyperplasia.
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Estradiol treatment of castrate dogs resulted in an increase in prostatic nuclear estrogen-receptor content, in the appearance of a putative prostatic cytosolic progesterone receptor, and in an alteration of the epithelium of the prostate to one characterized by squamous metaplasia. Treatment of castrate dogs with both estradiol and androstanediol resulted in a reducDr. Trachtenberg is a Fellow of the Medical Research Council of Canada.
Received for publication 15 October 1979 and in revised form 26 December 1979. tion in prostatic nuclear estrogen-receptor content, disappearance of the progesterone receptor, and loss of squamous metaplasia.
An increase in nuclear androgen-receptor content, thus, appears to be an important event in the development of both spontaneously arising and experimentally induced canine prostatic hyperplasia. The mechanism of androgen-estrogen synergism in the experimental induction of canine benign prostatic hyperplasia may be explained by estradiol-mediated increases in nuclear androgen-receptor content. Because androstanediol blocked certain estradiol-mediated events within the prostate, a negative feedback mechanism may exist in which the response of the canine prostate to estrogens is modulated by rising levels of androgen. INTRODUCTION The sensitivity of the canine prostate to androgens and estrogens is widely accepted. Canine prostatic hyperplasia, a common model for the study of the human disease, only develops in the presence of functioning testes (1, 2) and regresses after bilateral orchiectomy (3). It can be maintained or restored after castration by the administration of exogenous androgens (3, 4) and can be induced successfully in castrated young dogs with the administration of either dihydrotestosterone or androstanediol in combination with estradiol (5, 6) . Biochemically, canine prostatic hyperplasia has been characterized by the accumulation of dihydrotestosterone in prostatic tissue in concentrations five times normal (7) .
For biological action to occur, current concepts of steroid hormone action dictate the presence of specific receptor molecules (8) . These molecules bind with high affinity to steroid hormones within the cytosol and are translocated to the nucleus where the cellular response is initiated. Both androgen and estrogen receptors have l)een identified and characterized within the canine prostate (9, 10 Ill.), and the radioactivity counted with an efficiency of 34%. The data were analyzed by the method of Scatchard (14) [3H] estradiol to yield final labeled ligand concentrations of 0.15-10 nM. A parallel set of incubations was carried out with identical labeled ligand concentrations in the presence of a 100-fold excess of unlabeled estradiol to determine the amount of nonspecific binding. After incubation at 30°C for 20 h, free steroid was removed and specific binding was calculated and expressed as above.
Steroid specificity studies. 200 ,ul of cytosol or nuclear extract was incubated in triplicate in the presence of 10 nM [3H]R1881 alone or in the presence of 50 nM, 100 nM, or 1.0 ,uM unlabeled R1881 or progesterone. After incubation at 4°C for 24 h unbound and loosely bound steroid was removed with dextran-coated charcoal as described above; the amount of specifically bound [3H]R1881 was calculated for each concentration of unlabeled competing steroid. The percent inhibition of specifically bound R1881 was then plotted against the molar excess of the competitor, and the amount required for 50% inhibition was determined. The ratio of the concentration of unlabeled R1881 to that of progesterone required for 50% inhibition, times 100%, was termed the "relative binding affinity."
Protein and DNA measurements. Protein concentration was determined by measuring absorbances at 230 and 260 nm and correcting the values to milligrams per milliliter (A230 x 184) -(A260 x 76.1) = protein in micrograms per milliliter (15) .
DNA was measured by the method of Burton (16) (6) . Using the above criteria to define prostatic hyperplasia, three young intact (young benign prostatic hyperplasia [BPH] ) and all four of the old intact (old BPH) dogs were found to have prostatic hyperplasia (Table I) . Although the prostates of castrated untreated dogs uniformly displayed atrophic changes, those of estradiol-treated castrates were characterized by atrophy or squamous metaplasia (6) . Squamous metaplasia was never observed in any of the other groups. Androstanediol treatment alone restored the castrate prostate to a normal histological appearance, whereas the combined treatment with androstanediol and estradiol treatment induced prostatic hyperplasia (6) ( Table I) .
Androgen receptor. Cytosol and nuclear androgenreceptor contents were measured in the prostates of intact dogs with normal prostates and those with spontaneously arising prostatic hyperplasia (Table II) .
High affinity binding of [3H]R1881 was detected in all cases and no significant differences in apparent equilibrium dissociation constants were noted between groups (Table II) . Although no differences were noted in cytosolic androgen-receptor content in any ofthe intact groups, the prostatic nuclear androgenreceptor content of young dogs with spontaneously arising BPH was significantly greater than that of normal prostates of age-matched dogs (Table II) . The mean nuclear androgen-receptor content of old dogs with BPH, although higher than that of normal young dogs, was not significantlv different (Table II) .
In castrated dogs, high affinity androgen binding was detected in all groups and there were no significant differences in the apparent dissociation constants between groups. In untreated castrate dogs, cytosolic and nuclear androgen-receptor levels were low. Treatment with androstanediol increased both cytosolic and nuclear androgen-receptor levels to those observed in young control dogs (Table II) . Although prostatic weight was significantly increased to the weight normally seen in spontaneously developing BPH, histologically, the glands were normal (Table I) . Treatment of castrated dogs with androstanediol and estradiol resulted in levels of cytosolic androgen receptor comparable with those found in dogs treated with androstanediol alone. Nuclear androgen-receptor levels, however, were significantly greater than those encountered with androstanediol treatment (Table II) , and histological evidence of glandular hyperplasia was noted (Table I) .
In castrated dogs treated with estradiol, cytosolic and nuclear androgen-receptor content, as measured by R1881 binding, very significantly increased over levels found in control castrate animals (Table II) . It is well known that R1881 binds with high affinity to both the androgen and progesterone receptors (17, 18) ; in all other treatment groups, the steroid specificity of R1881 binding was characteristic for an androgen receptor (Table III) . However, the relative binding affinity of progesterone for R1881 binding sites in the cytosol of estradiol-treated castrates was 72+±9% compared with an average of 3% in the other treatment groups (Table III) . In our experience, the relative binding affinity of progesterone for R1881 binding to the androgen receptor in human and rat prostatic cytosol is 2-3%, whereas the relative binding affinity to cytosol containing a progesterone-binding molecule averages 36% (18, 19) . Thus, these data sug- (Table IV) . No differences in the apparent dissociation constants were detected between groups. In untreated intact dogs, no differences in cytosol or nuclear extract estrogen-receptor content were detected in any of the groups examined.
Cytosolic estrogen-receptor contents in all of the steroidtreated castrate dogs were not different (Table IV) dogs with BPH, one is able to investigate the disease at an active stage in its development (6) . The content of cytosolic androgen receptor in young normal and young hyperplastic prostates was not different. However, the content of prostatic nuclear androgen receptor was significantly greater in young dogs with prostatic hyperplasia than in age-matched animals with normal prostates. Similarly, castrate dogs treated with both androstanediol and estradiol in which prostatic hyperplasia was induced also showed an increase in nuclear but not cytosolic androgen-receptor content. Conversely, castrate young dogs that had been treated with androstanediol alone, and whose prostates were histologically normal, demonstrated androgenreceptor levels similar to those found in the intact normal prostate. Thus, an increase in nuclear but not cytosolic androgen-receptor content accompanies the occuirrence of prostatic hyperplasia in the young dog.
Steroid hormones are believed to act only in the presence of specific receptor molecules and to exert their major influence within the nucleus (25). Clark et al. (26) have stated that in the rat uterus true growth only occurs in the presence of and after a specific retention period of the nuclear steroid-receptor complex. We believe that elements of the above concepts are operational in the canine prostate. Because the cytosol is both the site of origin of the receptor and the major destination of receptor leaving the nucleus (25, 27) , then the constant cytosolic level of androgen receptor in the face of an elevated nuclear level of androgen receptor in hyperplastic prostates indicates nuclear accumulation of the steroid-receptor complex. This may be the result of increased cytoplasmic synthesis of receptor and subsequent nuclear translocation or a normal rate of production with decreased processing, thereby leading to nuclear accumulation (28, 29) . In either case, the level of nuclear androgen receptor appears to correlate with the development of prostatic hyperplasia because in both spontaneously arising and experimentally induced prostatic hyperplasia nuclear androgen-receptor content was elevated, whereas, in intact animals with normal prostates and androstanedioltreated animals with histologically normal prostates, nuclear androgen-receptor content was not elevated. Thus, elevated nuclear but not cytosolic androgenreceptor content not only accompanies the development of canine prostatic hyperplasia, but may play a direct role in the pathogenesis of this entity.
The development of BPH and the presence of elevated nuclear androgen-receptor content cannot, however, be viewed solely as the result of prolonged androgenic stimulation. Castrate dogs treated for 4 mo with androstanediol neither developed prostatic hyperplasia nor accumulated elevated levels of prostatic nuclear androgen receptor. The addition of estradiol to androstanediol therapy, however, uniformly resulted in both the development of BPH and increased nuclear androgen-receptor content. Estradiol, thus, appears to be able to enhance the androgenic activity of androstanediol. The mechanism of this interaction, however, is unclear. Moore et al. (13) Insight into the mechanism of action of estrogen in the canine prostate has been aided by the identification of a specific estrogen receptor (10) . In this study, we have demonistrated that treatmiient of castrates with estradiol results in an increase in both cytosolic and nuclear estrogen-receptor content and in the appearance of a cytosolic progesterone receptor. The latter finding has also beeni reported recenitly by Dube et al. (30) .
Furthermore, estrogen prodtuces a marked chatnge in the morplhological organization of the prostate fromii a predominantly atrophic epithelium to one characterized by s(luamiious metaplasia and fibromutseular stroma.
When castrate dogs are treated with both estradiol and androstaniediol, there is enhanced androgenic activity with a simnultaneous inhibition of estrogenic expression.
Thus, ntclear androgen-receptor content is sharply elevated in associationi wvith imarked hyperplasia of the epitheliumn and, in the presence of these increased androgenic events, there is a reduction in nuclear estrogen-recep)tor content (from levels preseint in estradiol-treated castrates), disappearance of the progesterone receptor, and loss of s(quanmous imetaplasia. The ability of androgen to block these estrogen-induced events has been demiionstrated in other species. Treatment with androgenis can block estrogen-induced increases in nuclear estrogen-receptor content in rat uterus (31) and estrogen inductioni of the progesterone receptor in the hamiister kidney (32) . These data stuggest that a negative feedback mechanismii may exist in which certain respoinses of the caninle prostate to estrogen may be modulated by rising levels of androgen.
This paper demonstrates that increased nctlear androgen-receptor content is a characteristic of both spontaneously occurring aind experimentally indtuced caniine prostatic hyperplasia. Furthermore, in the experimentally induced disease, the administration of estrogen increases nuclear androgen-receptor content that appears instrumnenital in the developmiienit of prostatic hyperplasia. Moore 
